Baidu
map

JAMA:花生皮肤贴片用于花生过敏儿童的疗效研究

2019-03-13 zhangfan MedSci原创

研究认为,花生蛋白贴剂可提高花生过敏儿童的过敏原耐受能力,但研究结果未达到统计学置信区间边界,其疗效有待进一步验证

目前尚无获批的花生过敏治疗方法。近日研究人员就皮肤免疫疗法对花生过敏儿童的疗效及安全性进行了考察。

356名4-11岁花生过敏儿童参与研究,患儿无严重过敏反应史,随机接受皮肤花生贴剂(含250μg花生蛋白,n=238)或安慰剂(n?=?118),研究的主要终点为接触花生蛋白刺激激发的客观反应,定义耐受剂量达到300mg以上的患儿为治疗响应者。

参与患儿平均年龄7岁,89.9%完成了研究,治疗依从率为98.5%。花生贴治疗组治疗响应率分35.3%,安慰剂组为13.6%,但未达到置信区间下限。最常见的不良事件为贴片部位反应,治疗组为95.4%,对照组为89%,治疗组10.5%以及对照组9.3%的患儿未完成研究。

研究认为,花生蛋白贴剂可提高花生过敏儿童的过敏原耐受能力,但研究结果未达到统计学置信区间边界,其疗效有待进一步验证。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1764161, encodeId=0c0d1e6416150, content=<a href='/topic/show?id=844492480bb' target=_blank style='color:#2F92EE;'>#贴片#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92480, encryptionId=844492480bb, topicName=贴片)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56f237637156, createdName=12498b37m84暂无昵称, createdTime=Tue Jun 25 00:47:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507087, encodeId=4da1150e087e4, content=<a href='/topic/show?id=43b7869368a' target=_blank style='color:#2F92EE;'>#花生过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86936, encryptionId=43b7869368a, topicName=花生过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1079863863, createdName=xfpan15, createdTime=Fri Mar 15 01:47:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362575, encodeId=d9283625e53b, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Wed Mar 13 14:09:06 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032097, encodeId=a408103209e0a, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Mar 13 13:47:00 CST 2019, time=2019-03-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1764161, encodeId=0c0d1e6416150, content=<a href='/topic/show?id=844492480bb' target=_blank style='color:#2F92EE;'>#贴片#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92480, encryptionId=844492480bb, topicName=贴片)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56f237637156, createdName=12498b37m84暂无昵称, createdTime=Tue Jun 25 00:47:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507087, encodeId=4da1150e087e4, content=<a href='/topic/show?id=43b7869368a' target=_blank style='color:#2F92EE;'>#花生过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86936, encryptionId=43b7869368a, topicName=花生过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1079863863, createdName=xfpan15, createdTime=Fri Mar 15 01:47:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362575, encodeId=d9283625e53b, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Wed Mar 13 14:09:06 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032097, encodeId=a408103209e0a, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Mar 13 13:47:00 CST 2019, time=2019-03-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1764161, encodeId=0c0d1e6416150, content=<a href='/topic/show?id=844492480bb' target=_blank style='color:#2F92EE;'>#贴片#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92480, encryptionId=844492480bb, topicName=贴片)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56f237637156, createdName=12498b37m84暂无昵称, createdTime=Tue Jun 25 00:47:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507087, encodeId=4da1150e087e4, content=<a href='/topic/show?id=43b7869368a' target=_blank style='color:#2F92EE;'>#花生过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86936, encryptionId=43b7869368a, topicName=花生过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1079863863, createdName=xfpan15, createdTime=Fri Mar 15 01:47:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362575, encodeId=d9283625e53b, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Wed Mar 13 14:09:06 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032097, encodeId=a408103209e0a, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Mar 13 13:47:00 CST 2019, time=2019-03-13, status=1, ipAttribution=)]
    2019-03-13 SCI我的梦

    谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1764161, encodeId=0c0d1e6416150, content=<a href='/topic/show?id=844492480bb' target=_blank style='color:#2F92EE;'>#贴片#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92480, encryptionId=844492480bb, topicName=贴片)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56f237637156, createdName=12498b37m84暂无昵称, createdTime=Tue Jun 25 00:47:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507087, encodeId=4da1150e087e4, content=<a href='/topic/show?id=43b7869368a' target=_blank style='color:#2F92EE;'>#花生过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86936, encryptionId=43b7869368a, topicName=花生过敏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1079863863, createdName=xfpan15, createdTime=Fri Mar 15 01:47:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362575, encodeId=d9283625e53b, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Wed Mar 13 14:09:06 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032097, encodeId=a408103209e0a, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Mar 13 13:47:00 CST 2019, time=2019-03-13, status=1, ipAttribution=)]
    2019-03-13 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

J Allergy Clin Immunol:伊布替尼或许能够预防食物过敏

近日,一项研究证明伊布替尼的短期治疗能够抑制皮肤试验反应并消除成年人中因花生或坚果过敏介导的嗜碱性粒细胞的活化。

JAMA:Viaskin可作为花生过敏的新型治疗方法

DBV Technologies是一家临床阶段的生物制药公司,近日宣布其关键的III期临床试验(PEPITES1试验)的详细结果已在美国医学会杂志(JAMA)上发表,该试验评估了Viaskin治疗4至11岁花生过敏儿童的有效性和安全性。

澳大利亚研究人员在花生过敏方面取得了突破

澳大利亚的研究人员报道了一项重大突破,他们发现了一种长期治疗方法,在不久的将来有望治愈致命的花生过敏症。在墨尔本的默多克儿童研究所(Murdoch children Research Institute)的科学家们进行的临床试验中,花生过敏的儿童在18个月的时间里服用了少量的花生蛋白。当实验在2013年结束时,大约80%的孩子能够忍受花生。周三发表在医学杂志《柳叶刀》上的这项研究发现,在随后四年的

Allergy:花生过敏的诊断方法比较!

由此可见,BAT显示了显著升高的CDsens相比于HR和被动HR。嗜碱性粒细胞检验的诊断性能差异不明显。不过,BAT可以诊断低嗜碱性粒细胞数的受试者,与HR相反。

Aimmune制药在2018 EAACI上公布AR101治疗花生过敏的全新临床数据

Aimmune制药是一家开发可能危及生命的食物过敏疗法的生物制药公司,Aimmune在2018年于德国慕尼黑举行的过敏、哮喘和免疫学大会(EAACI)上报告了AR101治疗花生过敏的关键性III期PALISADE临床试验的其他结果。Aimmune先前在4-17岁年龄组的试验达到了预先指定的主要和次要临床终点,而本次公布的数据提供了其他分析,包括在研究中接受治疗的成年人数据。

Aravax基于肽的免疫疗法治疗花生过敏展现出积极有利的1期临床试验结果

Aravax在2019年美国过敏、哮喘和免疫学会(AAAAI)年会上展示了最近完成的PVX108的第1阶段临床试验的阳性数据。数据充分肯定了PVX108的安全性,即使对严重花生过敏的患者也是如此。与花生过敏的其他治疗方法相比,这是一个显着的进步。

Baidu
map
Baidu
map
Baidu
map